News summary

Capillary-selective vasodilation through myosin inhibition halts ischaemic cascades

Source: Nature - Main • Published: 14 Oct 2026, 00:00

Summarized by Masters of Longevity from Nature - Main.

Reports a myosin-targeting small molecule that selectively relaxes capillary pericytes to reverse capillary no-reflow and improve outcomes across heart and kidney reperfusion models.

Capillary-selective vasodilation through myosin inhibition halts ischaemic cascades
Key Takeaways
  • R(+)2501 is a myosin-specific vasodilator that rapidly restores capillary blood flow in reperfused animal models.
  • Treatment with R(+)2501 reduced infarct size and markedly improved survival after acute myocardial ischemia in animals.
  • R(+)2501 reversed renal capillary no-reflow after myocardial infarction and restored kidney function in animal studies.
Read the full article at Nature - Main ↗

Continue exploring

Recommended MoL Picks

MoL PickMelatonin and Heart Failure: What the Evidence Actually ShowsA 2025 study linked melatonin use with heart failure. A 2026 analysis found no significant association. Their different designs explain why the question remains open.MoL PickCan Exergaming Improve Balance? What Older Adults Should KnowMotion-controlled games may make balance practice easier to repeat. The evidence supports a structured adjunct—not a fall-proofing shortcut.MoL PickCreatine and Cancer: Why New Mouse Studies Point in Opposite DirectionsCreatine strengthened antitumour immune cells in one mouse study—and promoted metastasis through platelets in another. The apparent contradiction reveals why neither result is a supplement recommendation.